ClinConnect ClinConnect Logo
Search / Trial NCT02700685

Effect of Pycnogenol® on ADHD

Launched by NINA HERMANS · Mar 4, 2016

Trial Information

Current as of June 19, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • The patient is between 6-12 years old (both inclusive).
  • The patient satisfies the DSM-IV criteria for ADHD or ADD.
  • The patient has a responsible caregiver who is able to provide information about the patient's functional status.
  • Written informed consent is obtained from the patient and the legally accepted representative.
  • Exclusion Criteria:
  • The patient does satisfy the DSM-IV for autism spectrum disorder.
  • The patient does have situational hyperactivity, pervasive developmental disorders, schizophrenia, other psychotic disorders such as mood or anxiety disorder, personality disorder as unsocial behaviour, personality change due to a general medical condition, mental retardation (IQ \< 70), understimulating environments, conduct disorder, chorea and other dyskinesias. The patient does not have tics or Tourette's syndrome, or personal or family history of psychotic disorder, bipolar illness, depression, or suicide attempt.
  • The patient does have any chronic medical disorder (diabetes, epilepsy or other seizure disorder, autoimmune disorder, gastrointestinal disorder, renal or cardiovascular disorders, etc.) or acute inflammatory disease. The patient does not have glaucoma, heart disease, heart rhythm disorder, high blood pressure, or peripheral vascular disease such as Raynaud's syndrome.
  • The patient did use any of these medications during the 3 months before entering the study: clonidine, guanethidine, blood thinners (e.g. warfarin or Coumadin), antidepressants (e.g. amitriptyline, citalopram, doxepin, fluoxetine, nortriptyline, paroxetine, sertraline), cold or allergy medicine that contains a decongestant, medications to treat high or low blood pressure, seizure medicine (e.g. phenobarbital, phenytoin, primidone), or diet pills.
  • The patient did take MAO inhibitor (isocarboxazid, linezolid, phenelzine, rasagiline, selegiline or tranylcypromine) in the past 14 days.
  • The patient has any other contraindication for the use of methylphenidate.
  • The patient did use vitamin/mineral/herbal/omega-3 supplements or other any medication (psychoactive medication, antibiotics, anti-inflammatory drugs, melatonin, etc.) \> 1 week during the 3 months before inclusion.

About Nina Hermans

Nina Hermans is a dedicated clinical trial sponsor focused on advancing innovative medical research to improve patient outcomes. With a commitment to ethical practices and regulatory compliance, Nina Hermans collaborates with leading researchers and healthcare institutions to design and execute clinical trials across various therapeutic areas. The organization prioritizes patient safety and scientific integrity, leveraging cutting-edge methodologies and data analytics to drive evidence-based decisions. Through its rigorous approach to clinical development, Nina Hermans aims to contribute valuable insights to the medical community and facilitate the timely delivery of new treatments to patients in need.

Locations

Ghent, , Belgium

Edegem, , Belgium

Borgerhout, , Belgium

Patients applied

0 patients applied

Trial Officials

Nina Hermans, PhD

Study Director

Universiteit Antwerpen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials